This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEWARK, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will be a panelist at the 2014 BIO International Convention on June 25, 2014 at 4:15 pm PDT. Mr. McGlynn will participate in the panel discussion, "How International Collaboration is Accelerating the Field." This panel will showcase examples of international collaboration that are producing results or initiating new approaches to cross-border research. Under Mr. McGlynn's leadership, StemCells, Inc. launched a multi-national Phase I/II trial in spinal cord injury. The pre-clinical activities were performed in the United States and followed by the initiation of the clinical trial in Switzerland, which was subsequently expanded to both Canada and the United States. The success of these programs is a great example of how international collaboration can produce results that positively impact the lives of patients across the globe. The 2014 BIO International Convention will take place June 23-26 at the San Diego Convention Center in San Diego, CA.
Additional information on the conference and the panel presentation can be found on the conference website at:
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company conducted a Phase I/II clinical trial in chronic spinal cord injury in Switzerland, Canada and the United States, and has reported positive interim data for the first eight patients. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD) in the United States. In addition, the Company is pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine (CIRM). StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells is available at
CONTACT: Greg Schiffman
Chief Financial Officer